Latest Conference Articles

January 26th 2020, 8:20pm

Gastrointestinal Cancers Symposium (ASCO GI)

A regimen of avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil in patients with RAS/BRAF-wildtype metastatic colorectal cancer induced a very high response rate but did not meet its primary progression-free survival end point.

January 26th 2020, 5:26am

Gastrointestinal Cancers Symposium (ASCO GI)

Peter R. Galle, MD, discusses the patient-reported outcomes results from the Phase III IMbrave150 study, which he presented at the 2020 Gastrointestinal Cancers Symposium

January 26th 2020, 1:48am

Gastrointestinal Cancers Symposium (ASCO GI)

Zev A. Wainberg, MD discusses the efficacy findings of pembrolizumab monotherapy versus chemotherapy for patients with PD-L1–positive advanced gastric and gastroesophageal junction cancer of high combined positive score in cohort 1 of the phase II KEYNOTE-059 and in the phase III KEYNOTE-061 and KEYNOTE-062 studies.

January 25th 2020, 11:57pm

Gastrointestinal Cancers Symposium (ASCO GI)

Scott Kopetz, MD, PhD, FACP, sheds light on encorafenib triplet and doublet options for patients with BRAF V600E–mutant metastatic colorectal cancer and other novel regimens under investigation.

January 25th 2020, 11:08pm

Gastrointestinal Cancers Symposium (ASCO GI)

The triplet regimen of nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) achieved clinically meaningful responses in patients with advanced hepatocellular carcinoma who were either sorafenib (Nexavar)-naïve, or resistant to or intolerant of sorafenib.

January 25th 2020, 9:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of gemcitabine plus cisplatin with or without veliparib is highly active in patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation.

January 25th 2020, 8:28pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with unresectable hepatocellular carcinoma who were randomized to first-line lenvatinib (Lenvima), compared with sorafenib (Nexavar), and received subsequent anticancer procedures experienced prolonged overall survival.

January 25th 2020, 2:24am

Gastrointestinal Cancers Symposium (ASCO GI)

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.

January 25th 2020, 2:00am

Gastrointestinal Cancers Symposium (ASCO GI)

The triplet combination of cabozantinib, nivolumab, and ipilimumab induced higher response rates, progression-free survival, and overall survival compared with nivolumab plus cabozantinib in patients with advanced hepatocellular carcinoma.

January 25th 2020, 12:58am

Gastrointestinal Cancers Symposium (ASCO GI)

The triplet of nivolumab, ramucirumab and paclitaxel showed promising antitumor activity with durable responses in a phase II study of patients with advanced gastric cancer.

January 24th 2020, 10:25pm

Gastrointestinal Cancers Symposium (ASCO GI)

Teresa Macarulla, MD, discusses a new finding from the phase III POLO trial regarding patients who rapidly progressed on treatment.

January 24th 2020, 9:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

The efficacy of larotrectinib has been confirmed in patients with heavily pretreated TRK fusion–positive gastrointestinal cancers.

January 24th 2020, 9:05pm

Gastrointestinal Cancers Symposium (ASCO GI)

Pembrolizumab monotherapy in the first and later lines of therapy leads to more durable responses and meaningfully improves overall survival compared with chemotherapy in patients with advanced gastric/gastroesophageal junction cancer with a high number of PD-L1–expressing cells in the tumor, lymphocytes, and macrophages.

January 22nd 2020, 10:36pm

Gastrointestinal Cancers Symposium (ASCO GI)

A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.

January 6th 2020, 11:01pm

State of the Science Summit on Hematologic Malignancies

Seo-Hyun Kim, MD, discusses frontline treatment considerations in stage III and IV classical Hodgkin lymphoma and exciting combinations on the horizon.

January 3rd 2020, 11:08pm

State of the Science Summit on Hematologic Malignancies

Jamile M. Shammo, MD, FASCP, FACP, discusses the current treatment paradigm of myelofibrosis, criteria for ruxolitinib resistance and intolerance, and promising agents on the horizon.

January 3rd 2020, 9:21pm

State of the Science Summit on Hematologic Malignancies

Parameswaran Venugopal, MD, discusses current and emerging treatment strategies in non-Hodgkin lymphoma.

January 2nd 2020, 9:14pm

State of the Science Summit on Genitourinary Cancers

Nancy B. Davis, MD, discusses the excitement with targeted therapies as well as anticipated combination strategies under investigation in advanced urothelial cancer.

December 28th 2019, 4:00pm

San Antonio Breast Cancer Symposium

A high absolute lymphocyte count at baseline appears to be an independent predictor for longer overall survival in patients with metastatic breast cancer who are treated with eribulin mesylate.

December 28th 2019, 12:00am

State of the Science Summit on Hematologic Malignancies

Melissa L. Larson, MD, discusses available treatments for patients with acute myeloid leukemia, as well as others that are in the pipeline.